Genome-based mutational analysis by next generation sequencing in patients with malignant pleural and peritoneal mesothelioma

Gamze Ugurluer, Kenneth Chang, Mauricio E. Gamez, Andrea L. Arnett, Ritujith Jayakrishnan, Robert C. Miller, Terence T. Sio

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background/Aim: Malignant mesothelioma is a rare malignancy with limited therapeutic options. Exome-based next-generation sequencing (NGS) techniques may direct the future of molecular targeting and improve systemic therapies for patients with mesothelioma. Materials and Methods: Eleven patients with NGS testing were selected, with a total of 236 somatic cancer-related mutations analyzed. Descriptive and Kaplan-Meier statistics were applied. Results: The median age was 65 years (range=27-73 years); 4 (36%) patients were females. Seven (64%) and four patients (36%) had pleural and peritoneal mesothelioma, respectively. Detectable mutations were found in 86% of the pleural and 50% of the peritoneal mesothelioma patients (overall, 73% of patients). The families of BAP1 (36%), CDKNA2A/B (27%) and NF2 (27%) represented the most frequently mutated genes. The median overall survival for all patients was 20.8 months, with 1- and 2-year survival rates of 91% and 40%, respectively. Conclusion: Genomic alterations as potential therapeutic targets were found by NGS. These findings will help in the development of new screening tools and targeting therapies, and in turn impact the standard-of-care and potentially lengthen disease control and survival periods in the future.

Original languageEnglish (US)
Pages (from-to)2331-2338
Number of pages8
JournalAnticancer Research
Volume36
Issue number5
StatePublished - 2016

Fingerprint

Mesothelioma
Genome
Exome
Mutation
Survival
Therapeutics
Standard of Care
Neoplasms
Survival Rate
Genes

Keywords

  • BAP1
  • CDKNA2A/B
  • Malignant mesothelioma
  • Molecular targeting therapy
  • Next-generation sequencing
  • NF2

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ugurluer, G., Chang, K., Gamez, M. E., Arnett, A. L., Jayakrishnan, R., Miller, R. C., & Sio, T. T. (2016). Genome-based mutational analysis by next generation sequencing in patients with malignant pleural and peritoneal mesothelioma. Anticancer Research, 36(5), 2331-2338.

Genome-based mutational analysis by next generation sequencing in patients with malignant pleural and peritoneal mesothelioma. / Ugurluer, Gamze; Chang, Kenneth; Gamez, Mauricio E.; Arnett, Andrea L.; Jayakrishnan, Ritujith; Miller, Robert C.; Sio, Terence T.

In: Anticancer Research, Vol. 36, No. 5, 2016, p. 2331-2338.

Research output: Contribution to journalArticle

Ugurluer, G, Chang, K, Gamez, ME, Arnett, AL, Jayakrishnan, R, Miller, RC & Sio, TT 2016, 'Genome-based mutational analysis by next generation sequencing in patients with malignant pleural and peritoneal mesothelioma', Anticancer Research, vol. 36, no. 5, pp. 2331-2338.
Ugurluer G, Chang K, Gamez ME, Arnett AL, Jayakrishnan R, Miller RC et al. Genome-based mutational analysis by next generation sequencing in patients with malignant pleural and peritoneal mesothelioma. Anticancer Research. 2016;36(5):2331-2338.
Ugurluer, Gamze ; Chang, Kenneth ; Gamez, Mauricio E. ; Arnett, Andrea L. ; Jayakrishnan, Ritujith ; Miller, Robert C. ; Sio, Terence T. / Genome-based mutational analysis by next generation sequencing in patients with malignant pleural and peritoneal mesothelioma. In: Anticancer Research. 2016 ; Vol. 36, No. 5. pp. 2331-2338.
@article{defeeadfe2094773a2df69edb8c0a489,
title = "Genome-based mutational analysis by next generation sequencing in patients with malignant pleural and peritoneal mesothelioma",
abstract = "Background/Aim: Malignant mesothelioma is a rare malignancy with limited therapeutic options. Exome-based next-generation sequencing (NGS) techniques may direct the future of molecular targeting and improve systemic therapies for patients with mesothelioma. Materials and Methods: Eleven patients with NGS testing were selected, with a total of 236 somatic cancer-related mutations analyzed. Descriptive and Kaplan-Meier statistics were applied. Results: The median age was 65 years (range=27-73 years); 4 (36{\%}) patients were females. Seven (64{\%}) and four patients (36{\%}) had pleural and peritoneal mesothelioma, respectively. Detectable mutations were found in 86{\%} of the pleural and 50{\%} of the peritoneal mesothelioma patients (overall, 73{\%} of patients). The families of BAP1 (36{\%}), CDKNA2A/B (27{\%}) and NF2 (27{\%}) represented the most frequently mutated genes. The median overall survival for all patients was 20.8 months, with 1- and 2-year survival rates of 91{\%} and 40{\%}, respectively. Conclusion: Genomic alterations as potential therapeutic targets were found by NGS. These findings will help in the development of new screening tools and targeting therapies, and in turn impact the standard-of-care and potentially lengthen disease control and survival periods in the future.",
keywords = "BAP1, CDKNA2A/B, Malignant mesothelioma, Molecular targeting therapy, Next-generation sequencing, NF2",
author = "Gamze Ugurluer and Kenneth Chang and Gamez, {Mauricio E.} and Arnett, {Andrea L.} and Ritujith Jayakrishnan and Miller, {Robert C.} and Sio, {Terence T.}",
year = "2016",
language = "English (US)",
volume = "36",
pages = "2331--2338",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Genome-based mutational analysis by next generation sequencing in patients with malignant pleural and peritoneal mesothelioma

AU - Ugurluer, Gamze

AU - Chang, Kenneth

AU - Gamez, Mauricio E.

AU - Arnett, Andrea L.

AU - Jayakrishnan, Ritujith

AU - Miller, Robert C.

AU - Sio, Terence T.

PY - 2016

Y1 - 2016

N2 - Background/Aim: Malignant mesothelioma is a rare malignancy with limited therapeutic options. Exome-based next-generation sequencing (NGS) techniques may direct the future of molecular targeting and improve systemic therapies for patients with mesothelioma. Materials and Methods: Eleven patients with NGS testing were selected, with a total of 236 somatic cancer-related mutations analyzed. Descriptive and Kaplan-Meier statistics were applied. Results: The median age was 65 years (range=27-73 years); 4 (36%) patients were females. Seven (64%) and four patients (36%) had pleural and peritoneal mesothelioma, respectively. Detectable mutations were found in 86% of the pleural and 50% of the peritoneal mesothelioma patients (overall, 73% of patients). The families of BAP1 (36%), CDKNA2A/B (27%) and NF2 (27%) represented the most frequently mutated genes. The median overall survival for all patients was 20.8 months, with 1- and 2-year survival rates of 91% and 40%, respectively. Conclusion: Genomic alterations as potential therapeutic targets were found by NGS. These findings will help in the development of new screening tools and targeting therapies, and in turn impact the standard-of-care and potentially lengthen disease control and survival periods in the future.

AB - Background/Aim: Malignant mesothelioma is a rare malignancy with limited therapeutic options. Exome-based next-generation sequencing (NGS) techniques may direct the future of molecular targeting and improve systemic therapies for patients with mesothelioma. Materials and Methods: Eleven patients with NGS testing were selected, with a total of 236 somatic cancer-related mutations analyzed. Descriptive and Kaplan-Meier statistics were applied. Results: The median age was 65 years (range=27-73 years); 4 (36%) patients were females. Seven (64%) and four patients (36%) had pleural and peritoneal mesothelioma, respectively. Detectable mutations were found in 86% of the pleural and 50% of the peritoneal mesothelioma patients (overall, 73% of patients). The families of BAP1 (36%), CDKNA2A/B (27%) and NF2 (27%) represented the most frequently mutated genes. The median overall survival for all patients was 20.8 months, with 1- and 2-year survival rates of 91% and 40%, respectively. Conclusion: Genomic alterations as potential therapeutic targets were found by NGS. These findings will help in the development of new screening tools and targeting therapies, and in turn impact the standard-of-care and potentially lengthen disease control and survival periods in the future.

KW - BAP1

KW - CDKNA2A/B

KW - Malignant mesothelioma

KW - Molecular targeting therapy

KW - Next-generation sequencing

KW - NF2

UR - http://www.scopus.com/inward/record.url?scp=84989929921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989929921&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - 2331

EP - 2338

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5

ER -